Scarica l'app Stockscreener
10.30
0.29%
0.03
Dopo l'orario di chiusura:
10.30
Precedente Chiudi:
$10.27
Aprire:
$10.27
Volume 24 ore:
190.05K
Relative Volume:
0.86
Capitalizzazione di mercato:
$512.62M
Reddito:
-
Utile/perdita netta:
$-119.67M
Rapporto P/E:
-3.7729
EPS:
-2.73
Flusso di cassa netto:
$-97.30M
1 W Prestazione:
+3.31%
1M Prestazione:
-16.33%
6M Prestazione:
-16.87%
1 anno Prestazione:
-5.59%
Intervallo 1D:
$10.07
$10.47
Intervallo di 1 settimana:
$9.565
$10.79
Portata 52W:
$8.58
$16.91
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Nome
Mineralys Therapeutics Inc
Settore
Industria
Telefono
(888) 378-6240
Indirizzo
150 N. RADNOR CHESTER ROAD, RADNOR
Confronta MLYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
10.30 | 512.62M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-10 | Iniziato | H.C. Wainwright | Buy |
| 2024-04-02 | Iniziato | Goldman | Buy |
| 2023-03-07 | Iniziato | BofA Securities | Buy |
| 2023-03-07 | Iniziato | Credit Suisse | Outperform |
| 2023-03-07 | Iniziato | Evercore ISI | Outperform |
| 2023-03-07 | Iniziato | Guggenheim | Buy |
| 2023-03-07 | Iniziato | Stifel | Buy |
| 2023-03-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Mineralys Therapeutics Inc Borsa (MLYS) Ultime notizie
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.1%Here's What Happened - MarketBeat
(MLYS) Technical Data - Stock Traders Daily
Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development - MSN
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha
Barclays PLC Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLC - Defense World
When (MLYS) Moves Investors should Listen - Stock Traders Daily
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares - MarketBeat
Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus.com
Insider Sell: Adam Levy Sells Shares of Mineralys Therapeutics I - GuruFocus.com
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock - MarketBeat
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock By Investing.com - Investing.com Nigeria
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock - Investing.com India
Mineralys therapeutics CFO Adam Levy sells $97,863 in stock - Investing.com
Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians - Patient Care Online
Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension - MSN
Jane Street Group LLC Has $192,000 Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionRADNOR, PA – January 8, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company f - Defense World
Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - Yahoo Finance
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial By Investing.com - Investing.com Nigeria
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat - Diagnostic and Interventional Cardiology
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6%Here's Why - MarketBeat
Mineralys Therapeutics : Corporate Overview January 2025 - Marketscreener.com
Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial - Investing.com
Mineralys Gets FDA Green Light for Sleep Apnea Drug Trial, Targets 54M Patient Market - StockTitan
Objective long/short (MLYS) Report - Stock Traders Daily
Neumora shares sink following Phase III flop in MDD - MSN
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Geode Capital Management LLC - Defense World
Barclays PLC Buys 28,208 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
State Street Corp Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Trading 4% Higher – Still a Buy? - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4%Here's What Happened - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.1%Here's Why - MarketBeat
(MLYS) Trading Report - Stock Traders Daily
Mineralys Therapeutics (NASDAQ:MLYS) Trading 3% Higher – Still a Buy? - Defense World
Mineralys Therapeutics (NASDAQ:MLYS) Trading 3% HigherWhat's Next? - MarketBeat
Franklin Resources Inc. Boosts Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
Wellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - The Eastern Progress Online
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8%Here's Why - MarketBeat
Charles Schwab Investment Management Inc. Buys 9,664 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World
Mineralys Therapeutics Inc Azioni (MLYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):